Navigation Links
Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available

FRAZER, Pa., Jan. 7 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that the presentation slides that will be used by the company at the JPMorgan Healthcare Conference are now available on the "Investor Information" section of the company's website at On Tuesday, January 8, 2008, Frank Baldino, Jr., Ph.D., Chairman and CEO, will deliver a one hour presentation at the Conference beginning at 2:00 p.m. Pacific Time (5 p.m. Eastern Time).

Live Web Cast and Archived Replay

Members of the financial and investment community, the media and other interested parties can access a live web cast of the presentation through the Investor Information section of the company's website Following the live presentation, a replay of the presentation will be available for two weeks on the Company's website.

About Cephalon, Inc.

Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. Cephalon's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at or by calling 1-800-896-5855.

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
2. Cephalon Submits Supplemental New Drug Application for FENTORA
3. Cephalon Announces Strong Third Quarter Financial Results
4. Cephalon Quarterly Conference Call Invitation
5. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
6. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
7. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference
11. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Imagine Exhibitions and Universal Partnerships ... opening in March 2016 at Melbourne Museum in Melbourne, Australia. Immediately following the ... American tour dates. The Exhibition is based on Universal Pictures’ Jurassic World, one ...
(Date:11/30/2015)... DIEGO , Nov. 30, 2015  HUYA Bioscience ... China,s pharmaceutical innovations, today announced it ... Drug Development Fund (KDDF) to foster collaboration between KDDF ... development and commercialization of healthcare products for the global ... as an important source of new innovative preclinical and ...
(Date:11/30/2015)... -- Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW Bio"), a ... solid tumor cancers, announced today that the Board is ... Company welcomes Neil Woodford,s call for an ... report on NW Bio.  The Company,s Board is under ... stated, "We agree with Mr. Woodford that, at NW ...
(Date:11/27/2015)... CHESTERFIELD, United Kingdom , Nov. 27, 2015 /PRNewswire/--  ... specialty biopharmaceutical company, announced today that it has closed ... systems (CMDS) business to Guerbet (GBT- NYSE Euronext) in ... CMDS operations encompassed four manufacturing facilities and a total ... nearly 75 in the St. Louis ...
Breaking Biology Technology:
(Date:11/26/2015)... 2015 Research and Markets ( ) ... Sensors - Technology and Patent Infringement Risk Analysis" ... --> Fingerprint sensors using capacitive technology ... fingerprint sensor vendor Idex forecasts an increase of 360% ... devices and of the fingerprint sensor market between 2014 ...
(Date:11/18/2015)... Nov. 18, 2015  As new scientific discoveries deepen ... and other healthcare providers face challenges in better using ... patients. In addition, as more children continue to survive ... adulthood and old age. John M. Maris, ... Hospital of Philadelphia (CHOP) . --> ...
(Date:11/17/2015)... 17, 2015  Vigilant Solutions announces today that Mr. ... of Directors. --> --> ... from the partnership at TPG Capital, one of the ... $140 Billion in revenue.  He founded and led TPG,s ... TPG companies, from 1997 to 2013.  In his first ...
Breaking Biology News(10 mins):